Condition: Acute Exacerbation of Idiopathic Pulmonary Fibrosis · Sponsor: Fondation Hôpital Saint-Joseph
Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed. This confirmation is mandatory to validate the improvement of the prognosis of EA-IPF under this treatment but also to search for unsuspected deleterious effects as it has been shown with immunosuppressants in stable idiopathic pulmonary fibrosis.
This description comes directly from the study's public registry record.
Jean-Marc NACCACHE, MD · 144126747 · jmnaccache@ghpsj.fr
Helene BEAUSSIER, PharmD, PhD · 144127883 · crc@ghpsj.fr
Always discuss trial participation with your own doctor first.
| CHU ANgers | Angers, France | Recruiting |
| CHU de Besancon | Besançon, France | Recruiting |
| Hôpital Avicenne | Bobigny, France | Not Yet Recruiting |
| CHU BOrdeaux | Bordeaux, France | Recruiting |
| CHU Caen | Caen, France | Recruiting |
| CHU Clermont-Ferrand | Clermont-Ferrand, France | Not Yet Recruiting |
| CHIC | Créteil, France | Recruiting |
| CHU de Dijon | Dijon, France | Recruiting |
| CHU Grenoble | Grenoble, France | Not Yet Recruiting |
| CHRU Lille | Lille, France | Not Yet Recruiting |
| Hospices Civils de Lyon | Lyon, France | Recruiting |
| Hôpital Nord | Marseille, France | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05674994